Anti-Human B7-H3 Reference Antibody (Mirzotamab, RUO) (HV612036)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HV612036
Description	Mirzotamab (HV612036) is a research-grade recombinant antibody targeting CD276. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Humanized
Isotype	IgG1-kappa
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	CD276, B7-H3, Costimulatory molecule, B7H3, 4Ig-B7-H3, B7 homolog 3, CD276 antigen
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	Q5ZPR3
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	ABBV-155, 2229859-11-2
Background	CD276 antigen (B7-H3) is a ~57 kDa protein. May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. May be involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy. Both isoform 1 and isoform 2 appear to be redundant in their ability to modulate CD4 T-cell responses. CD276 is the therapeutic target of omburtamab (clinical).
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

SEC-HPLC

SEC-HPLC detection for Research Grade Mirzotamab.
Bioactivity

Detects CD276/B7-H3 in indirect ELISAs.
SDS-PAGE

SDS-PAGE for Research Grade Mirzotamab.
Flow CytoMetry

Flow-cytometry using APC anti-human CD276 antibody. PC-3 cells were stained with an irrelevant antibody (Blue Histogram) or an APC anti-human CD276 monoclonal antibody (Catalog: HV612036, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.
Flow CytoMetry

Flow-cytometry using FITC anti-human CD276 antibody. PC-3 cells were stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human CD276 monoclonal antibody (Catalog: HV612036, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.
Flow CytoMetry

Flow-cytometry using PE anti-human CD276 antibody. PC-3 cells were stained with an irrelevant antibody (Blue Histogram) or an PE anti-human CD276 monoclonal antibody (Catalog: HV612036, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.
Western blot

Western blot analysis was performed using anti-CD276 monoclonal antibody at 1μg/ml on various samples.
Lane 1: recombinant human CD276 (Catalog No: HV612011)